8-K filed May 6, 2026 at 16:06 ET
Vanda Pharmaceuticals reported Q1 2026 revenue of $51.7M (+3% YoY), in line with modest growth, but EPS of -$0.82 missed the Street consensus of -$0.53 by 55% as net loss widened to $48.6M. Positives include 26% Fanapt growth, FDA approval of BYSANTI, NEREUS launch, and raised FY2026 revenue guidance to $240-290M (from $230-260M). The mixed results balance a significant EPS miss against strong pipeline and commercial catalysts.